Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's reversal of its April 2005 acquisition of endovascular aortic aneurysm repair device developer TriVascular puts the newly independent entity back in the hands of its original management team in exchange for $30 million and a minority equity stake

You may also be interested in...

Device/Diagnostics Quarterly Deal Statistics, Q4 2013

Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.

New Products In Brief

Financings In Brief

TriVascular raises $60 million: European launch of the firm's Ovation abdominal aortic aneurysm stent graft later this year will be aided by $60 million in new funding led by Pinnacle Ventures, including a "Series C" equity financing and growth capital venture debt, the firm announced July 12. The low-profile stent system is designed to expand the patient population suitable for endovascular aortic repair by addressing a wider range of diseased anatomy, the company explains. European study implants began last March to support a CE mark application, and the firm commenced its U.S. pivotal study in May. A 2008 spinout from Boston Scientific headquartered in Santa Rosa, Calif., TriVascular notes that it also is developing a version of Ovation for thoracic aortic aneurysms (1"The Gray Sheet" April 7, 2008)

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts